Search - tctmd.com

Displaying 21 - 40 of 60

Sort: Relevancy | Date

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

High Glycemic Index Diets Linked to CVD and Mortality

Michael O'Riordan

February 24, 2021

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Todd Neale

September 18, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

Advertisement

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

High Glycemic Index Diets Linked to CVD and Mortality

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content